The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension

The BREELIB nebulizer was developed for iloprost to reduce inhalation times for patients with pulmonary arterial hypertension (PAH). This multicenter, randomized, unblinded, four-part study compared inhalation time, pharmacokinetics, and acute tolerability of iloprost 5 µg at mouthpiece delivered vi...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Pulm Circ
Glavni autori: Gessler, Tobias, Ghofrani, Hossein-Ardeschir, Held, Matthias, Klose, Hans, Leuchte, Hanno, Olschewski, Horst, Rosenkranz, Stephan, Fels, Lueder, Li, Na, Ren, Dawn, Kaiser, Andreas, Schultze-Mosgau, Marcus-Hillert, Müllinger, Bernhard, Rohde, Beate, Seeger, Werner
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2017
Teme:
Research Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5467944/
https://ncbi.nlm.nih.gov/pubmed/28597762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045893217706691
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items